Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

395 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Completed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

NCT00919139

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +25 more
Locations
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Alta Bates Summit Comprehensive Cancer Center Berkeley, California, United States
  • Peninsula Medical Center Burlingame, California, United States
  • University of California Davis Cancer Center Sacramento, California, United States
View all 207 locations
View Trial Details
Completed

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00003416

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • MBCCOP - University of South Alabama Mobile, Alabama, United States
  • CCOP - Greater Phoenix Phoenix, Arizona, United States
  • Veterans Affairs Medical Center - Phoenix (Hayden) Phoenix, Arizona, United States
  • Veterans Affairs Medical Center - Tucson Tucson, Arizona, United States
View all 84 locations
View Trial Details
Completed

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00352443

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +43 more
Locations
  • USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States
  • University of California Davis Cancer Center Sacramento, California, United States
  • University of Colorado Cancer Center at UC Health Sciences Center Aurora, Colorado, United States
  • Lucille P. Markey Cancer Center at University of Kentucky Lexington, Kentucky, United States
View Trial Details
Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

NCT00082784

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, +33 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Pittsburgh, Pennsylvania, United States
  • Medical University of South Carolina Charleston, South Carolina, United States
View Trial Details

Related conditions